Phase 1/2 × Pancreatic Neoplasms × Clear all
NCT07410676 2026-02-18

EBNK-ST-001

Essen Biotech

Phase 1/2 Recruiting
83 enrolled
NCT06128551 2026-02-10

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Revolution Medicines, Inc.

Phase 1/2 Recruiting
534 enrolled